금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Stocks Rise Pre-Bell as Traders Await Fed Policy Decision, Inflation Report, Big Tech Earnings
The benchmark US stock measures pointed higher before the opening bell Monday as traders gear up for...
Stock market today: Dow, S&P 500, Nasdaq futures rise ahead of busy week of earnings, Fed rate decision
Investors braced for a full earnings docket and the Federal Reserve's next policy decision this week...
British Pound: Stronger PMIs lean hawkish for BoE – Danske Bank
Danske Research Team notes UK flash PMIs strengthened in October, with the composite rising to 53.1 ...
Take-Two Interactive (TTWO) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Take-Two Interactive (TTWO) closed at $242.92, marking a -1.82% move from the previous day.
OceanFirst expects Q4 2026 net interest margin of 3.09%-3.14% following Flushing integration
Mission Valley Bancorp GAAP EPS of $0.54, revenue of $10.7M
Church & Dwight projects 4% to 5% organic sales growth and $1.175B operating cash flow for 2026 amid MISS MOUTH’s expansion
SA Asks: Tesla hit a new 52-week low this week. Is it a buy?
Dow Jones Futures: Market Rebounds, Now Watch For This; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom
The stock market bounced but hasn't taken this step while a key risk is growing. SpaceX, AMD, Sandisk, Eli Lilly earnings loom.
'We let you down': Leopold Aschenbrenner's mea culpa to fund investors after near-collapse
Abqaiq Is a Warning That Oil Markets May Be Misreading
While the dust is settling and facts emerge, it is clear that the latest attack on Saudi Aramco's Abqaiq oil-processing complex is rapidly becoming one of the most consequential energy developments of ...
United States CFTC S&P 500 NC Net Positions declined to $-17.2K from previous $-16.8K
Eurozone CFTC EUR NC Net Positions declined to €-72.4K from previous €-41.3K
Japan CFTC JPY NC Net Positions declined to ¥-163.4K from previous ¥-152.1K
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?
There is more to this stock than meets the eye.